This content is only available within our institutional offering.
23 Oct 2019
MORPHOSYS: The amyloid approach is still very much alive | BUY | EUR125(+27%)
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
MORPHOSYS: The amyloid approach is still very much alive | BUY | EUR125(+27%)
- Published:
23 Oct 2019 -
Author:
Eric Le Berrigaud -
Pages:
3
MORPHOSYS - BUY | EUR125(+27%)
The amyloid approach is still very much alive
What’s going on with aducanumab (Biogen)?
Greater exposure to high dose is needed to show clinical effect
What does this mean for gantenerumab (Roche/MorphoSys)?